The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.

Methods for helping to monitor subject adherence with a prescribed antipsychotic drug treatment regimen are disclosed.

Methods for helping to monitor subject adherence with a prescribed antipsychotic drug treatment regimen are disclosed.

Systems and methods for a color board for use in reagent strip testing are disclosed. One implementation may include a color board surface, a first colored reference element printed on the color board surface, and a second colored reference element printed on the color board surface. The color board may also include a test region on the color board surface configured to receive at least one reagent pad. The color board may also include a unique code, and the code may reflect specific chromatic properties associated with each of the first colored reference element and the second color reference element at a time of printing. The unique code may be machine readable to enable a machine to later normalize a comparison color, for determining chromatic properties of the at least one reagent pad.

Systems and methods for a color board for use in reagent strip testing are disclosed. One implementation may include a color board surface, a first colored reference element printed on the color board surface, and a second colored reference element printed on the color board surface. The color board may also include a test region on the color board surface configured to receive at least one reagent pad. The color board may also include a unique code, and the code may reflect specific chromatic properties associated with each of the first colored reference element and the second color reference element at a time of printing. The unique code may be machine readable to enable a machine to later normalize a comparison color, for determining chromatic properties of the at least one reagent pad.

Non-limiting embodiments of methodologies for preparing diagnostic assay(s) calibrator(s), calibration material(s), and/or control(s), as well as kits, devices, and method(s) of calibration related thereto.

A method of calibrating a device for measuring the concentration of creatinine in a sample including one or more enzyme modulators, the method comprising: determining sensitivities of the device for each of two or more calibration solutions, wherein each calibration solution has a different amount of enzyme modulator; determining a degree of modulation for each of the two or more calibration solutions; determining a degree of modulation for a sample to be measured; and calculating the sensitivity of the device for the sample, wherein said calculating comprises modifying the sensitivity of one of the two or more calibration solutions by a function comprising the determined degrees of modulation.

A method of calibrating a device for measuring the concentration of creatinine in a sample including one or more enzyme modulators, the method comprising: determining sensitivities of the device for each of two or more calibration solutions, wherein each calibration solution has a different amount of enzyme modulator; determining a degree of modulation for each of the two or more calibration solutions; determining a degree of modulation for a sample to be measured; and calculating the sensitivity of the device for the sample, wherein said calculating comprises modifying the sensitivity of one of the two or more calibration solutions by a function comprising the determined degrees of modulation.

The present invention provides: a marker for determining critical stage kidney disease by using an indicator value based on the amount of D-alanine in the blood or the amount of D-alanine and L-alanine therein; a blood analysis method which uses said marker for patients undergoing surgery or intensive care; and a blood analysis system for determining critical stage kidney disease in patients undergoing surgery or intensive care.

The present invention provides: a marker for determining critical stage kidney disease by using an indicator value based on the amount of D-alanine in the blood or the amount of D-alanine and L-alanine therein; a blood analysis method which uses said marker for patients undergoing surgery or intensive care; and a blood analysis system for determining critical stage kidney disease in patients undergoing surgery or intensive care.